Deep brain stimulation (DBS) represents an important emerging therapy for epilepsy, according to Professor Jukka Peltola of the University of Tampere in Tampere, Finland. At AES 2018, he discussed his experience with neurostimulation and how to identify patients most likely to benefit from this approach.
In most cases, potential candidates for neurostimulation have epilepsy that is refractory to at least 2 antiepileptic regimens (monotherapy or combination therapy) and are likely being evaluated for surgical resection, according to Prof. Peltola.
“I think it’s important to discuss the option of neuromodulation already at the initial evaluation for surgery,” he said. He estimated that only 10–30% of his patients are eligible for surgery, and the remaining 70–90% need to know that other options are available.
Möchten Sie mehr lesen?
Loggen Sie sich ein oder registrieren Sie sich, um Zugang zu allen Inhalten von Neurodiem zu erhalten.
Sie haben bereits einen Account? Einloggen
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.